A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

Background: As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer’s disease (AD) in 64 countries. Methods: This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and tolerability of the 5-cm2 (9-mg loading dose; 4.6 mg/24...

Full description

Bibliographic Details
Main Authors: Yu Nakamura, Yukimichi Imai, Masahiro Shigeta, Ana Graf, Toru Shirahase, Hyosung Kim, Akifumi Fujii, Joji Mori, Akira Homma
Format: Article
Language:English
Published: Karger Publishers 2011-06-01
Series:Dementia and Geriatric Cognitive Disorders Extra
Subjects:
Alzheimerߣs disease
Cholinesterase inhibitors
Japanese
Randomized clinical trial
Rivastigmine
Online Access:http://www.karger.com/Article/FullText/328929

Internet

http://www.karger.com/Article/FullText/328929

Similar Items